EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Chardan Capital issued their FY2025 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($2.92) for the year. Chardan Capital has a "Buy" rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.
Several other brokerages also recently commented on EYPT. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price target on the stock. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $26.63.
View Our Latest Analysis on EYPT
EyePoint Pharmaceuticals Stock Performance
Shares of EyePoint Pharmaceuticals stock traded down $0.36 during trading on Thursday, reaching $5.47. The company's stock had a trading volume of 187,337 shares, compared to its average volume of 815,309. The business's fifty day moving average price is $6.79 and its 200-day moving average price is $8.23. EyePoint Pharmaceuticals has a one year low of $5.40 and a one year high of $23.65. The firm has a market cap of $375.88 million, a price-to-earnings ratio of -2.73 and a beta of 1.41.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million.
Hedge Funds Weigh In On EyePoint Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of EYPT. California State Teachers Retirement System boosted its holdings in shares of EyePoint Pharmaceuticals by 3.8% in the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after acquiring an additional 1,797 shares in the last quarter. Legal & General Group Plc boosted its stake in EyePoint Pharmaceuticals by 4.4% in the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock worth $345,000 after purchasing an additional 1,932 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 39.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after purchasing an additional 1,940 shares during the last quarter. Invesco Ltd. increased its stake in shares of EyePoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company's stock valued at $117,000 after buying an additional 2,177 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in EyePoint Pharmaceuticals by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock worth $113,000 after buying an additional 2,782 shares in the last quarter. Institutional investors own 99.41% of the company's stock.
EyePoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
